
Beckley Psytech, a private company in the psychedelics space, announced that it has begun training psychotherapists for a Phase 2 clinical trial with 5-MeO-DMT, a strong and fast-acting psychedelic compound naturally produced by the Sonoran Desert Toad.
The company launched a program to study 5-MeO-DMT-assisted psychotherapy in patients with treatment-resistant depression, reaching over $100 million in private financing by August 2021.